Get the Stockscreener App
33.94
3.89%
1.27
After Hours:
34.20
0.26
+0.77%
Cogent Biosciences Inc stock is traded at $33.94, with a volume of 2.78M.
It is up +3.89% in the last 24 hours and down -7.80% over the past month.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.
See More
Previous Close:
$32.67
Open:
$33.225
24h Volume:
2.78M
Relative Volume:
1.39
Market Cap:
$5.80B
Revenue:
-
Net Income/Loss:
$-354.30M
P/E Ratio:
-13.45
EPS:
-2.5234
Net Cash Flow:
$-286.27M
1W Performance:
+8.61%
1M Performance:
-7.80%
6M Performance:
-15.97%
1Y Performance:
+604.15%
1-Day Range:
$32.87
$34.19
1-Week Range:
$31.48
$34.19
52-Week Range:
$4.795
$43.73
Cogent Biosciences Inc Stock (COGT) Company Profile
Name
Cogent Biosciences Inc
Sector
Industry
Phone
617-945-5576
Address
275 WYMAN STREET, WALTHAM
Compare COGT vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
COGT
Cogent Biosciences Inc
|
33.94 | 5.58B | 0 | -354.30M | -286.27M | -2.5234 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cogent Biosciences Inc Stock (COGT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-16-26 | Resumed | Jefferies | Buy |
| Nov-10-25 | Upgrade | Stifel | Hold → Buy |
| Nov-10-25 | Upgrade | Wedbush | Neutral → Outperform |
| Oct-16-25 | Initiated | Stifel | Hold |
| Sep-03-25 | Initiated | Raymond James | Strong Buy |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Dec-11-24 | Downgrade | Needham | Buy → Hold |
| Feb-26-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Feb-08-24 | Initiated | Citigroup | Buy |
| Dec-11-23 | Downgrade | Wedbush | Outperform → Neutral |
| Dec-08-23 | Initiated | JP Morgan | Overweight |
| Apr-28-23 | Initiated | Robert W. Baird | Outperform |
| Mar-27-23 | Resumed | H.C. Wainwright | Buy |
| Dec-14-22 | Initiated | Needham | Buy |
| Jun-28-22 | Initiated | Guggenheim | Buy |
| Oct-11-21 | Initiated | H.C. Wainwright | Buy |
| Jun-09-21 | Resumed | Jefferies | Buy |
| Dec-23-20 | Initiated | Piper Sandler | Overweight |
| Oct-14-20 | Initiated | Ladenburg Thalmann | Buy |
View All
Cogent Biosciences Inc Stock (COGT) Latest News
Assessing Cogent Biosciences (COGT) Valuation After A Strong Year And Recent Share Price Pullback - Yahoo Finance
Why is Cogent Biosciences stock up 4% today? By Investing.com - Investing.com Canada
Why is Cogent Biosciences stock up 4% today? - Investing.com
COGT Stock Chart | COGENT BIOSCIENCES INC (NASDAQ:COGT) - ChartMill
Cogent Biosciences (COGT) CEO Robbins gifts 320,000 shares in estate move - Stock Titan
COGT SEC FilingsCogent Biosciences Inc 10-K, 10-Q, 8-K Forms - Stock Titan
A Look At Cogent Biosciences (COGT) Valuation After New APEX And JAK2 Data Presentations Are Announced - Sahm
Could 2026 Mark A Transformational Year For Cogent Biosciences? - RTTNews
Cogent Biosciences (NASDAQ: COGT) group reports 9,043,903 shares - Stock Titan
Cogent Biosciences Announces Presentations of Pivotal APEX Trial Data and JAK2 V617F Program at EHA Congress 2026 - Moomoo
Cogent Biosciences Announces Multiple Presentations at the European Hematology Association (EHA) 2026 Congress - The Manila Times
TradingKey - TradingKey
Cogent Biosciences (COGT) Receives a Rating Update from a Top Analyst - The Globe and Mail
Pier Capital LLC Buys Shares of 46,260 Cogent Biosciences, Inc. $COGT - MarketBeat
Analysts Offer Insights on Healthcare Companies: Novo Nordisk (NVO), OnKure Therapeutics (OKUR) and Cogent Biosciences (COGT) - The Globe and Mail
Cogent Biosciences, Inc. $COGT Shares Purchased by Vanguard Group Inc. - MarketBeat
LifeSci Capital Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $55 - Moomoo
Piper Sandler Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $52 - Moomoo
Cogent Biosciences (COGT) Valuation After Wider Q1 Loss And Bezuclastinib Regulatory Progress - Yahoo Finance
A Quick Look at Today's Ratings for Cogent Biosciences(COGT.US), With a Forecast Between $45 to $55 - Moomoo
A Look At Cogent Biosciences (COGT) Valuation After First Quarter Earnings Loss And Strong One Year Share Price Run - Sahm
H.C. Wainwright raises Cogent stock price target to $55 on cash runway - Investing.com UK
Understanding the Setup: (COGT) and Scalable Risk - Stock Traders Daily
Cogent Biosciences Reports Recent Business Highlights and First Quarter 2026 Financial Results - Investing News Network
Cogent Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Cogent Biosciences (NASDAQ:COGT) Posts Quarterly Earnings Results, Hits Expectations - MarketBeat
Cogent Biosciences Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Bezuclastinib NDAs and cash into 2028 at Cogent Biosciences (NASDAQ: COGT) - Stock Titan
Cogent Biosciences 1Q 2026: Net loss $(97.4)M, EPS $(0.53) — 10-Q Summary - TradingView
Biotechnology company Cogent Biosciences, Inc.'s latest financial data shows that as of the end of the first quarter of 2026, the company held a total of $866.4 million in cash and cash equivalents. - Bitget
Cogent Biosciences (COGT) boosts cash to fund bezuclastinib NDAs and launch plans - Stock Titan
Cogent Biosciences Q1 net loss widens on higher expenses - TradingView
Cogent plans two bezuclastinib launches, says cash lasts into 2028 - Stock Titan
BRIEF-Cogent Biosciences Q1 Income From Operations USD -103.607 Million - TradingView
MSN Money - MSN
Pictet Asset Management Holding SA Boosts Holdings in Cogent Biosciences, Inc. $COGT - MarketBeat
Cogent Biosciences, Inc. (NASDAQ:COGT) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Cogent Biosciences Inc (NASDAQ:COGT) Shows Bullish Technical Breakout Setup with High Scores - ChartMill
Systemic Mastocytosis (SM) Treatment Market 2026-2035: - GlobeNewswire
Systemic Mastocytosis (SM) Treatment Market 2026-2035: Industry to More Than Double in Size, Led by Sanofi, AdvaCare Pharma, and Cogent Biosciences - Yahoo Finance
Teachers Retirement System of The State of Kentucky Invests $1.33 Million in Cogent Biosciences, Inc. $COGT - MarketBeat
Cogent Biosciences, Inc. (NASDAQ:COGT) Sees Large Drop in Short Interest - MarketBeat
Cogent Biosciences (COGT) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat
Cogent Biosciences prices equity offering and 1.625% convertible senior notes - MSN
COGT Rise as FDA Accepts Bezuclastinib NDA in Non-Advanced SM - MSN
A Look At Cogent Biosciences (COGT) Valuation After New KRAS And ErbB2 Data At AACR 2026 - Sahm
The Technical Signals Behind (COGT) That Institutions Follow - Stock Traders Daily
[ARS] Cogent Biosciences, Inc. SEC Filing - Stock Titan
Cogent Biosciences Inc Stock (COGT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cogent Biosciences Inc Stock (COGT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Fairmount Funds Management LLC | Director |
Mar 31 '26 |
Sale |
34.66 |
7,000,000 |
242,620,000 |
5,503,418 |
| Fairmount Funds Management LLC | Director |
Jan 22 '26 |
Sale |
36.40 |
3,500,000 |
127,400,000 |
5,503,418 |
0.98%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):